Filing Flows › Standard Biotools (LAB) › R&D spending
Standard Biotools (LAB) R&D spending by quarter
Standard Biotools' R&D spending was $2.1M in Q3 2026 (third quarter 2026), +5% from Q2 2026. Over the last 7 quarters it ranged from $2.0M (Q2 2026) to $11.3M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.1M | +5% | -67% |
| Q2 2026 | $2.0M | -7% | -68% |
| Q1 2026 | $2.1M | -73% | -81% |
| Q4 2025 | $8.0M | +25% | — |
| Q3 2025 | $6.4M | +2% | — |
| Q2 2025 | $6.2M | -45% | — |
| Q1 2025 | $11.3M | — | — |
Q3 2026 at a glance
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Standard Biotools' R&D spending?
Standard Biotools' R&D spending was $2.1M in Q3 2026 (third quarter 2026), +5% from Q2 2026.
How has Standard Biotools' R&D spending changed?
Over the last 7 quarters it ranged from $2.0M (Q2 2026) to $11.3M (Q1 2025).